Freakonomics Radio
Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
- SOURCES:
- Chris Snyder, professor of economics at Dartmouth College.
- David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
- Heather Stone, health science policy analyst at the Food & Drug Administration.
- Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.
- RESOURCES:
- Chasing My Cure: A Doctor’s Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
- Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
- Market Shaping Accelerator.
- CURE ID Registry.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
435. Why Are Cities (Still) So Expensive?
It isn’t just supply and demand. We look at the complicated history and skewed incentives that make “affordable housing” more punch line than reality in cities from New York and San Francisco to Flint, Michigan…
434. Is New York City Over?
The pandemic has hit America’s biggest city particularly hard. Amidst a deep fiscal hole, rising homicides, and a flight to the suburbs, some people think the city is heading back to the bad old 1970s.…
“Don’t Neglect the Thing That Makes You Weird” | People I (Mostly) Admire: Ken Jennings
It was only in his late twenties that America’s favorite brainiac began to seriously embrace his love of trivia. Now he holds the “Greatest of All Time” title on Jeopardy! Steve Levitt digs into how…
433. How Are Psychedelics and Other Party Drugs Changing Psychiatry?
Three leading researchers from the Mount Sinai Health System discuss how ketamine, cannabis, and ecstasy are being used (or studied) to treat everything from severe depression to addiction to PTSD. We discuss the upsides, downsides,…
432. When Your Safety Becomes My Danger
The families of U.S. troops killed and wounded in Afghanistan are suing several companies that did reconstruction there. Why? These companies, they say, paid the Taliban protection money, which gave them the funding — and…
“One Does Not Know Where an Insight Will Come From” | People I (Mostly) Admire: Kerwin Charles
The dean of Yale’s School of Management grew up in a small village in Guyana. During his unlikely journey, he has researched video-gaming habits, communicable disease, and why so many African-Americans haven’t had the kind…
Does Anyone Really Know What Socialism Is? (Ep. 408 Rebroadcast)
Trump says it would destroy us. Biden needs the voters who support it (especially the Bernie voters). The majority of millennials would like it to replace capitalism. But what is “it”? We bring in the…
What if Your Company Had No Rules?
Netflix co-founder Reed Hastings came to believe that corporate rules can kill creativity and innovation. In this latest edition of the Freakonomics Radio Book Club, guest host Maria Konnikova talks to Hastings about his new…
431. Why Can’t Schools Get What the N.F.L. Has?
Thanks to daily Covid testing and regimented protocols, the new football season is underway. Meanwhile, most teachers, students, and parents are essentially waiting for the storm to pass. And school isn’t even a contact sport…
“I Started Crying When I Realized How Beautiful the Universe Is” | People I (Mostly) Admire Ep. 2: Mayim Bialik
She’s best known for playing neurobiologist Amy Farrah Fowler on The Big Bang Theory, but the award-winning actress has a rich life outside of her acting career, as a teacher, mother — and a real-life…